Rhenman & Partners Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Rhenman & Partners Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-200,000	Closed	-$2.15M	–	97
2015 Q3	$2.15M	Buy	200,000 +29,085	+17%	+$318K	0.34%	77
2015 Q2	$1.38M	Sell	170,915 -56,914	-25%	-$418K	0.17%	93
2015 Q1	$1.51M	Hold	227,829	–	–	0.25%	85
2014 Q4	$1.45M	Buy	227,829 +185,714	+441%	+$1.5M	0.42%	78
2014 Q3	$416K	Hold	42,115	–	–	0.12%	97
2014 Q2	$475K	Hold	42,115	–	–	0.14%	94
2014 Q1	$510K	Sell	42,115 -742	-2%	-$9.48K	0.15%	90
2013 Q4	$540K	Buy	+42,857	New	+$682K	0.21%	80

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Rhenman & Partners Asset Management's LXRX Position: Q4 2015 in Review

Rhenman & Partners Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2015, closing a stake of 200,000 shares — an estimated $2.15M sold.

Rhenman & Partners Asset Management first reported a position in LXRX in Q4 2013 and held it in 8 quarters. The position peaked at $2.15M in Q3 2015. 118 funds tracked by Wall St. Rank hold LXRX as of Q4 2015.

Rhenman & Partners Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Rhenman & Partners Asset Management sold 200,000 Lexicon Pharmaceuticals shares in Q4 2015, an estimated $2.15M.
Rhenman & Partners Asset Management first reported a position in Lexicon Pharmaceuticals in Q4 2013 and held it in 8 quarters.
Rhenman & Partners Asset Management's Lexicon Pharmaceuticals position peaked at $2.15M in Q3 2015.
118 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2015.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.